NCT04191499 2026-03-17INAVO120Hoffmann-La RochePhase 2/3 Active not recruiting325 enrolled 14 charts 1 FDA
NCT03006172 2026-03-11To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerGenentech, Inc.Phase 1 Active not recruiting200 enrolled
NCT07405801 2026-03-09A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerHoffmann-La RochePhase 2 Recruiting80 enrolled
NCT07054190 2026-02-27A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerHoffmann-La RochePhase 2 Recruiting60 enrolled